melatonin has been researched along with Eye Disorders in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bright light treatment is the most potent melatonin suppressor and circadian phase shifter and is a safe nonpharmacologic antidepressant for seasonal depression." | 4.82 | Circadian phase shifting, alerting, and antidepressant effects of bright light treatment. ( Oren, DA; Postolache, TT, 2005) |
| "Melatonin has been also used as a complementary treatment in anaesthesia, hemodialysis, in vitro fertilization and neonatal care." | 2.46 | Clinical uses of melatonin: evaluation of human trials. ( Mediavilla, MD; Reiter, RJ; Sánchez-Barceló, EJ; Tan, DX, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiello, A | 1 |
| Accardi, G | 1 |
| Crooke, A | 2 |
| Huete-Toral, F | 2 |
| Colligris, B | 2 |
| Pintor, J | 2 |
| Turner, PL | 1 |
| Van Someren, EJ | 1 |
| Mainster, MA | 1 |
| Sánchez-Barceló, EJ | 1 |
| Mediavilla, MD | 1 |
| Tan, DX | 2 |
| Reiter, RJ | 2 |
| Craiu, AM | 1 |
| Martínez-Águila, A | 1 |
| Postolache, TT | 1 |
| Oren, DA | 1 |
| Siu, AW | 1 |
| Maldonado, M | 1 |
| Sanchez-Hidalgo, M | 1 |
| Leino, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder[NCT00502320] | Phase 4 | 50 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinician-rated measure of mood; evaluates classical 21 Hamilton Depression items, and 8-item subscale measuring atypical depression symptoms which commonly occur during SAD episodes. Score ranges from 0-89, higher scores indicate higher levels of depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 19.99 | 15.97 | 19.47 | 20.65 | 23.68 |
| Ramelteon | 22.68 | 16.16 | 14.81 | 11.69 | 9.15 |
Self-rated scale to measure severity of depressive symptoms. Score ranges from 25-100, higher scores reflect more depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 58.63 | 56.40 | 58.59 | 58.62 | 61.65 |
| Ramelteon | 63.06 | 54.35 | 53.51 | 49.26 | 46.14 |
Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Score ranges from 0-21, higher scores represent more significant sleep disturbance. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 11.45 | 8.67 | 8.62 | 9.88 | 9.61 |
| Ramelteon | 11.56 | 9.52 | 7.57 | 8.07 | 7.05 |
6 reviews available for melatonin and Eye Disorders
| Article | Year |
|---|---|
The role and therapeutic potential of melatonin in age-related ocular diseases.
Topics: Aging; Autophagy; Eye Diseases; Humans; Melatonin; Neovascularization, Physiologic; Nitrosative Stre | 2017 |
Clinical uses of melatonin: evaluation of human trials.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Communicable Diseases; Endocrine System Diseases; | 2010 |
[About entropy in ophthalmology].
Topics: Biological Evolution; Cataract; Entropy; Eye Diseases; Humans; Kinetics; Lens, Crystalline; Melatoni | 2010 |
Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential.
Topics: Animals; Disease Models, Animal; Drug Design; Eye Diseases; Humans; Melatonin | 2012 |
Circadian phase shifting, alerting, and antidepressant effects of bright light treatment.
Topics: Adaptation, Physiological; Adult; Bipolar Disorder; Circadian Rhythm; Depression; Eye Diseases; Fema | 2005 |
Protective effects of melatonin in experimental free radical-related ocular diseases.
Topics: Antioxidants; Cataract; Eye Diseases; Glaucoma; Humans; Keratitis; Melatonin; Ocular Physiological P | 2006 |
3 other studies available for melatonin and Eye Disorders
| Article | Year |
|---|---|
Aging Successfully: The Role of Genetics and Environment in the Era of the Aging-Boom. Potential Therapeutic Implications.
Topics: Aging; Epigenesis, Genetic; Eye Diseases; Humans; Immune System; Longevity; Melatonin; Methotrexate; | 2019 |
The role of environmental light in sleep and health: effects of ocular aging and cataract surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cataract Extraction; Child; Circadian | 2010 |
6-Methoxy-tetrahydro-beta-carboline and melatonin in the human retina.
Topics: Adult; Aged; Carbolines; Child; Eye Diseases; Humans; Indoles; Mass Spectrometry; Melatonin; Middle | 1984 |